ADC Therapeutics (ADCT) Q1 2026 earnings review
Cost Reductions Take Effect While the Market Waits for LOTIS-5
ADC Therapeutics reported a stable 26Q1 with net product revenues of $20.0M, representing a 15% YoY increase driven by both volume and price. However, total revenue decelerated by 9% YoY due to a difficult comparison against a $5M milestone payment received in 25Q1. The real highlight of the quarter was financial discipline: total operating expenses fell 10% YoY, cutting the net loss to $33.0M. With $231M in cash, the company remains fully funded into 2028. The investment narrative, however, completely hinges on clinical execution, with the pivotal LOTIS-5 (2L+ DLBCL) topline data expected in 26Q2.
🐂 Bull Case
With $231.0 million in cash, the company has secured a runway into at least 2028. This easily bridges the gap through the 26Q2 LOTIS-5 data readout and the 2026 year-end LOTIS-7 readout, removing near-term dilution risk.
The strategic reprioritization initiated in 2025 is yielding tangible results. Adjusted total operating expenses fell 13% YoY to $42.9 million, substantially reducing the cash burn.
🐻 Bear Case
While ZYNLONTA net product revenue grew 15% YoY, it dipped sequentially from $22.3M in 25Q4 to $20.0M. The 3L+ DLBCL monotherapy market alone cannot sustain the business model; everything relies on expanding the label.
Despite broader cost-cutting, Selling and Marketing expenses accelerated to $12.7 million (up 20% YoY) ahead of potential label expansions. If LOTIS-5 fails, this bloated commercial infrastructure will become a severe liability.
⚖️ Verdict: ⚪
Neutral. Management is executing well on capital preservation, and ZYNLONTA base revenues are stable. However, the stock remains a binary play on the impending LOTIS-5 data expected next quarter.
Key Themes
R&D Expense Reductions Realized
Research and development expenses decelerated dramatically, dropping 31% YoY from $28.9 million to $19.9 million. This was driven by the discontinuation of non-core programs and the completion of IND-enabling activities for the PSMA-targeting ADC. This disciplined capital allocation is the primary reason the cash runway extends into 2028.
LOTIS-5 Topline Data Approach
The Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab (LOTIS-5) is the most critical near-term driver. Topline results are anticipated in 26Q2, with full data by year-end. Management expects this to support an sBLA submission before year-end, potentially opening up the larger 2L+ DLBCL market and triggering a revenue growth inflection starting in 2027.
ZYNLONTA Core Sales Volume Growth
Net product revenue grew to $20.0M, a 15% increase vs 25Q1. Management confirmed this was driven by both underlying volume increases and favorable pricing, suggesting stable demand in the 3L+ setting despite normal customer ordering pattern variability.
Personnel Shifting to Commercial Manufacturing
While R&D costs fell, management shifted $2.1M of personnel costs into Cost of Product Sales ($1.2M), Inventory Capitalization ($0.6M), and Selling & Marketing ($0.3M). This shift from clinical to commercial manufacturing reflects preparation for higher volumes. This strategy front-loads expenses and risks margin compression if LOTIS-5 label expansions do not materialize to absorb this new manufacturing capacity.
Milestone Reliance Masks Underlying Growth
Total revenue reversed from 25Q1, dropping 9% YoY (from $23.0M to $20.9M), entirely contradicting the positive narrative surrounding the 15% core product sales growth. This drop highlights the company's reliance on lumpy licensing and milestone revenues, which fell from $5.6M down to $0.8M this quarter.
LOTIS-7 Glofitamab Combination Strategy
The Phase 1b LOTIS-7 trial evaluating ZYNLONTA with Roche's glofitamab is progressing. Enrollment for the 150 µg/kg dose cohort will complete in H1 2026, with full data targeted for year-end 2026. This combination is strategically vital as it targets the 'complex therapy' segment of DLBCL and provides a defense against emerging bispecific competition.
Other KPIs
Accelerating improvement. Down from -$24.0 million in 25Q1. This non-GAAP metric strips out $3.2M in share-based compensation and significant non-cash interest related to the HCR deferred royalty obligation ($8.7M), providing a clearer picture of the actual cash-operating deficit, which is narrowing nicely.
Stable. Down from $261.3 million at the end of 2025. The ~$30 million sequential decrease was primarily driven by operating cash burn and seasonal annual bonus payments. Despite the drop, the cash balance remains highly robust relative to the quarterly burn rate.
Guidance
Stable. Management reiterated that current cash is sufficient to fund operations at least into 2028, assuming maintenance of minimum liquidity covenants on their debt. This completely derisks the 2026/2027 clinical readout periods from equity dilution.
Stable. The timeline for the Phase 3 confirmatory trial remains on track for the second quarter of 2026, which will serve as the pivotal binary event for the stock this year.
Key Questions
Commercial Expense Acceleration
Selling and marketing expenses grew 20% YoY. How much of this is structural buildup ahead of the anticipated LOTIS-5 expansion, and how flexible is this cost base if the sBLA submission timeline is delayed?
Manufacturing Cost Shifts
With $1.2M in personnel costs shifting into Cost of Product Sales, COGS nearly doubled YoY to $3.6M. Should we view this 18% gross margin as the new baseline going forward as you prep for broader commercialization?
PSMA-Targeting ADC Partnerships
Now that IND-enabling activities are complete for the PSMA-targeting ADC, what is the timeline for securing a partnership, and will you hold off on clinical entry until a partner is finalized to protect the cash runway?